Bruce Brockman
Optometrist · Ojai, CANPI 1922012632
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $685 of the $799 with a category attached, or 85.7%. It is spread thinly across 8 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $279 and has fallen 56.2% since, to $122 in 2025.
Across 9 payments — averaging $88.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$165
- Astellas Pharma US Inc$122
- Tarsus Pharmaceuticals, Inc.$122
- Alcon$118
- Coopervision Inc.$118
- Optos, Inc.$114
- plus $39 from 2 others
What the payments were for
- Food & beverage$68586%
- Entertainment$11414%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 1 | $165 |
| Astellas Pharma US Inc | 1 | $122 |
| Tarsus Pharmaceuticals, Inc. | 1 | $122 |
| Alcon | 2 | $118 |
| Coopervision Inc. | 1 | $118 |
| Optos, Inc. | 1 | $114 |
| Glaukos Corporation | 1 | $28 |
| ABB Con-cise Optical Group LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PANORAMIC OPHTHALMOSCOPE$228
- OCT OPHTHALMOSCOPE$228
- SAPIEN 3 Ultra RESILIA$165
- Izervay$122
- XDEMVY$122
- MyDay Contact Lens$118
- NFC-700$114
How this compares
$799 in reported general payments places this provider in the 55th percentile of 6,778 optometrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Latanoprost | 97 | $1,112 |
| Prednisolone Acetate | 35 | $1,025 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 24 | $278 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Ojai
- Steve YoelinNewport Beach$4.1M
- Matthew GellerSpring Valley$3.5M
- Melissa EricksonDavis$522K
- Omid KhodaiLake Forest$499K
- Jason TuSan Diego$351K
- Scott SchachterPismo Beach$312K
- Alicia LauSan Diego$300K
- Vin DangBakersfield$284K
- Steven FerrucciSepulveda$272K
- Katie ChuRosemead$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.